5-Azacytidine Promotes an Inhibitory T-Cell Phenotype and Impairs Immune Mediated Antileukemic Activity
Demethylating agent, 5-Azacytidine (5-Aza), has been shown to be active in treatment of myeloid malignancies. 5-Aza enhances anticancer immunity, by increasing expression of tumor-associated antigens. However, the impact of 5-Aza immune responses remains poorly understood. Here, T-cell mediated tumo...
Saved in:
Main Authors: | Thomas Stübig, Anita Badbaran, Tim Luetkens, York Hildebrandt, Djordje Atanackovic, Thomas M. C. Binder, Boris Fehse, Nicolaus Kröger |
---|---|
Format: | Article |
Language: | English |
Published: |
Wiley
2014-01-01
|
Series: | Mediators of Inflammation |
Online Access: | http://dx.doi.org/10.1155/2014/418292 |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Comment on “5-Azacytidine Promotes an Inhibitory T-Cell Phenotype and Impairs Immune Mediated Antileukemic Activity”
by: Thomas Mørch Frøsig, et al.
Published: (2015-01-01) -
Towards the Application of Atorvastatin to Intensify Proapoptotic Potential of Conventional Antileukemic Agents In Vitro
by: Jolanta D. Żołnierczyk, et al.
Published: (2015-01-01) -
Rationale and design of the multicenter, national, randomized, open labeled phase III trial: allogeneic stem cell transplantation as a potential curative treatment for patients with relapsed or progressed multiple myeloma (AlloRelapseMM Study)
by: Annemarie Glöckner, et al.
Published: (2025-01-01) -
Physiological Properties of Supragranular Cortical Inhibitory Interneurons Expressing Retrograde Persistent Firing
by: Barbara Imbrosci, et al.
Published: (2015-01-01) -
The Role of Allogeneic Stem Cell Transplantation in Relapsed/Refractory Hodgkin's Lymphoma Patients
by: Evgeny Klyuchnikov, et al.
Published: (2011-01-01)